Thus, existing pre-clinical and clinical data suggest a prominent role for NLRP3 blockade in metastatic breast cancers, underscoring OLT1177 in combination with anti-PD-1 as a valid treatment option. This evidence concerns the gene NLRP3 and breast carcinoma.